1.51 BONUS! Study Time Reduction Using Surrogate End Points with Dr. Emerson Chen
In this BONUS episode, we sit down for a quick in…
Plenary Session - inactive due to federal service · Plenary Session - inactive due to federal service
April 2, 201925m 47sExplicit
Audio is streamed directly from the publisher (feeds.soundcloud.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this BONUS episode, we sit down for a quick interview with Dr. Emerson Chen of OHSU on his recent paper in JAMA Internal Medicine on how using surrogate end points as opposed to overall survival for FDA approval for oncology drugs only results in a reduced drug development time of approximately 11 months.
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351
Back us on Patreon! www.patreon.com/plenarysession
Topics
medicineoncologyhealthpolicy